Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    November 2022
  1. LIN YC, Lin HF, Wu CC, Chen CL, et al
    Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity.
    J Gastroenterol. 2022;57:913-925.
    PubMed     Abstract available


    September 2022
  2. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    J Gastroenterol. 2022 Sep 29. pii: 10.1007/s00535-022-01925.
    PubMed     Abstract available


  3. SATAKE T, Morizane C, Rikitake R, Higashi T, et al
    The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry.
    J Gastroenterol. 2022 Sep 26. pii: 10.1007/s00535-022-01920.
    PubMed     Abstract available


    August 2022
  4. ZHOU Q, Wang X, Li R, Wang C, et al
    Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Aug 3. pii: 10.1007/s00535-022-01910.
    PubMed    


    July 2022
  5. KODAMA K, Kawaoka T, Kosaka M, Johira Y, et al
    Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
    J Gastroenterol. 2022 Jul 18. pii: 10.1007/s00535-022-01887.
    PubMed     Abstract available


  6. ZHOU Q, Wang X, Li R, Wang C, et al
    Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Jul 11. pii: 10.1007/s00535-022-01895.
    PubMed     Abstract available


  7. LIU T, Liao S, Mo J, Bai X, et al
    LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.
    J Gastroenterol. 2022 Jul 8. pii: 10.1007/s00535-022-01901.
    PubMed     Abstract available


  8. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    PubMed     Abstract available


    June 2022
  9. KARIYAMA K, Hiraoka A, Kumada T, Yasuda S, et al
    Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    J Gastroenterol. 2022 Jun 28. pii: 10.1007/s00535-022-01883.
    PubMed     Abstract available


    May 2022
  10. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    PubMed     Abstract available


    April 2022
  11. NISHIDA N, Yamakawa M, Shiina T, Mekada Y, et al
    Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.
    J Gastroenterol. 2022;57:309-321.
    PubMed     Abstract available


  12. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    PubMed     Abstract available


    March 2022
  13. SUZUKI Y, Mori T, Momose H, Matsuki R, et al
    Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.
    J Gastroenterol. 2022 Mar 31. pii: 10.1007/s00535-022-01868.
    PubMed     Abstract available


  14. LIN W, Lin J, Li J, Lin Y, et al
    Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
    J Gastroenterol. 2022 Mar 4. pii: 10.1007/s00535-022-01866.
    PubMed     Abstract available


    February 2022
  15. WANG XH, Hu ZL, Fu YZ, Hou JY, et al
    Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    J Gastroenterol. 2022 Feb 13. pii: 10.1007/s00535-022-01855.
    PubMed     Abstract available


    January 2022
  16. SAKAMORI R, Yamada R, Tahata Y, Kodama T, et al
    The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    J Gastroenterol. 2022 Jan 22. pii: 10.1007/s00535-021-01842.
    PubMed     Abstract available


  17. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available


  18. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    PubMed     Abstract available


    December 2021
  19. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    PubMed     Abstract available


  20. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    PubMed     Abstract available


  21. KAMADA Y, Takahashi H, Shimizu M, Kawaguchi T, et al
    Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
    J Gastroenterol. 2021;56:1045-1061.
    PubMed     Abstract available


    November 2021
  22. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    PubMed     Abstract available


  23. YONEDA M, Yamamoto T, Honda Y, Imajo K, et al
    Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    J Gastroenterol. 2021;56:1022-1032.
    PubMed     Abstract available


    September 2021
  24. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available


  25. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
    Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
    PubMed     Abstract available


    July 2021
  26. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.
    PubMed    


  27. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available


  28. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.
    PubMed    


    May 2021
  29. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    PubMed     Abstract available


    January 2021
  30. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.
    PubMed    


  31. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    PubMed     Abstract available


  32. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    PubMed     Abstract available


    August 2020
  33. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    PubMed     Abstract available


    December 2019
  34. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: